Company Overview of Parion Sciences, Inc.
Parion Sciences, Inc., a development stage biopharmaceutical company, engages in the research, development, and commercialization of treatments to restore patient’s innate mucosal surface defenses. The company focuses on respiratory and ocular diseases in which the patient’s ability to protect their mucosal surfaces is compromised. Its pipeline products include P-1037, a clinical stage ENaC blocker that maintain mucus hydration and accelerate pulmonary mucus clearance with a long duration of action for the treatment of cystic fibrosis (CF); tPAD, a novel trans-nasal pulmonary aerosol delivery system for treatment of CF; novel mucolytic agents that target mucus structure to facilitate mucus c...
2800 Meridian Parkway
Durham, NC 27713
Founded in 1999
Key Executives for Parion Sciences, Inc.
Chief Executive Officer and President
Co-Founder and Co-Chairman
Co-Founder and Co-Chairman
Senior Director of Clinical & Regulatory Operations
Compensation as of Fiscal Year 2015.
Parion Sciences, Inc. Key Developments
Parion Sciences Expands to Include Pediatric Cystic Fibrosis Population
Sep 10 15
Parion Sciences announced that the CLEAN-CF enrollment criteria for the study of P-1037 would be expanded to include people with Cystic Fibrosis (CF) between the ages of 12 and 17 years of age. The trial had previously enrolled people with CF age 18 and above only. The expansion of the age criteria for enrollment was based on a pre-specified safety review by the Data Monitoring Committee (DMC). The CLEAN-CF study includes people with CF regardless of an individual's genetic mutation. Based on preclinical studies, inhibiting the epithelial sodium channels (ENaC) in the airways with P-1037 (also known as VX-371), an ENaC blocker is expected to re-hydrate the mucus layers, thus helping to improve airway clearance and potentially lung function. P-1037 has demonstrated to be long acting in preclinical models and the Phase 2 evaluation is supported by the safety and tolerability profile observed in the completed Phase 1 studies. The initiation of the Phase 2 clinical trials was supported by an award from Cystic Fibrosis Foundation Therapeutics Inc.
Parion Sciences Licenses Epithelial Sodium Channel Inhibitors to Vertex Pharmaceuticals
Jun 5 15
Vertex Pharmaceuticals and Parion Sciences have entered into collaboration for the development of investigational epithelial sodium channel (ENaC) inhibitors to treat cystic fibrosis (CF) and other pulmonary diseases. As part of the deal, Vertex will have worldwide development and commercial rights to Parion's investigational ENaC inhibitors, including P-1037 and P-1055. Parion will receive an upfront payment of $80 million and will be eligible to receive up to an additional $490 million in development and regulatory milestone payments for development of ENaC inhibitors in CF, including $360 million related to global filing and approval milestones. Vertex will be responsible for future development activities for P-1037 and P-1055, which are indicated for the treatment of CF and other pulmonary diseases. Currently, P-1037 is being evaluated in an exploratory Phase IIa study in about 120 people with CF, regardless of genotype.
Parion Sciences Announces Initiation of Phase 2 Clinical Trial of P-1037 for the Treatment of Cystic Fibrosis
May 6 15
Parion Sciences announced that it has begun enrollment of a phase 2 clinical trial of P-1037 in patients with Cystic Fibrosis. The trial has been named the 'CLEAN-CF' trial which refers to 'Clearing Lungs with ENaC inhibition in Cystic Fibrosis'. The CLEAN-CF study will include CF patients regardless of an individual's genetic mutation. Inhibiting the epithelial sodium channels (ENaC) in the airways with P-1037, an 'ENaC blocker', is expected to re-hydrate the mucus layers, thus restoring airway clearance, improve lung function and, ultimately, reduce exacerbations. P-1037 has demonstrated to be long acting in preclinical models and to have a favorable safety and tolerability profile in the completed Phase 1 studies. Parion expects to enroll approximately 120 patients at 30 sites, most within CFFT's clinical trials national network.
Similar Private Companies By Industry
Recent Private Companies Transactions